Illumina, Roche accused of infringing genetic testing patents
07-12-2020
BGI wins partial lifting of Illumina injunction
13-08-2020
Natera and Illumina settle litigation, agree mutual licence
14-05-2020
Sundry Photography / Shutterstock.com
Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Illumina, Grail, cancer detection, oncology, mergers and acquisitions, M&A, Jeff Bezos, Bill Gates
